BirdoTech
Branden Lee
Dir. Business DevelopmentGenetron Health
Mr. Evan Xu
Chief Financial OfficerHelsinn Pharmaceuticals China
Kawin
The turnover in 2019 is over 800 million RMB (115 millon USD).
We are now in IPO process and projected to be listed in China this year.
Mr. Yu Cai
BD HEADPhastar
PHASTAR is a specialist biometrics CRO offering statistical consulting, clinical trial reporting, data management and data science services by providing expert consultants and managing and delivering in-house projects, FSP-style arrangements and preferred partnerships.
Our number one priority is ensuring on time, quality work: every project undertaken is supervised on methodology and utilizes internal processes designed to guarantee optimal quality, inspired by 3,700 years accumulated technical experience across the company.
PHASTAR is headquartered in London (UK) and North Carolina (US) and has 12 offices across five continents. PHASTAR is also currently in the process of setting up an office in Shangai, China.
Mr. Edward Clark
DirectorTasly Biopharmaceuticals Co., Ltd.
Tasly Biopharma with its headquarter in Shanghai focuses on the development of biologic drugs in the therapeutic areas of cardiovascular diseases, oncology and autoimmune, and alimentary tract and metabolism. Our target therapeutic areas are among the largest and fastest growing therapeutic areas in China, where biologics are expected to become one of the key growth drivers.
Pro-UK is an innovative biologics drug manufactured and commercialized by Tasly Biopharma, which is indicated for STEMI thrombolysis with a better efficacy and safety profile than alteplas. In addition to Pro-UK, we have a rich biopharmaceutical products under development.
Tasly has collaborated with various overseas companies, including Transgene, Pharnext, EA, Eli Lilly, APbio, etc.. Some of the assets from collaboration have been successfully transferred to China, and clinical trials have been initiated.
Tasly is actively looking for partnerships on clinical-stage to marketed assets, through straight licensing, co-development, strategic investment, etc. in the abovementioned disease areas to bring the asset to China market.